Proteomic Profiling of Human Extracellular Vesicles Reveals Diagnostic Biomarkers for Colon Adenocarcinoma.

TitleProteomic Profiling of Human Extracellular Vesicles Reveals Diagnostic Biomarkers for Colon Adenocarcinoma.
Publication TypeJournal Article
Year of Publication2026
AuthorsSeo Y, Han YDae, Bojmar L, Kim K-A, Seo Y, Kim TK, Lee S, Kim Y, Bin Choi H, Lim YH, Kim CHyun, Sandberg A, Fan C, Lauritzen P, Molina H, Peralta C, Geri JB, Burdette C, Han DHoon, Gee HYung, Lee I, Shin J-S, Kim H, Li L, Tobias GC, Wortzel I, Shin SJoon, Jung H-I, Lee MGoo, Paik S, Schwartz RE, Ahn JBae, Lyden D, Kim HSang
JournalJ Extracell Vesicles
Volume15
Issue4
Paginatione70278
Date Published2026 Apr
ISSN2001-3078
KeywordsAdenocarcinoma, Adult, Aged, Biomarkers, Tumor, Colonic Neoplasms, Extracellular Vesicles, Female, Humans, Male, Middle Aged, Proteome, Proteomics, Tandem Mass Spectrometry
Abstract

Early detection of colon adenocarcinoma (COAD) remains suboptimal. Fecal tests fail to diagnose 30% of stage I cancer, and serum CEA lacks sensitivity (< 40%). Extracellular vesicles (EVs) circulate systemically and package tumor-related cargo, making them attractive non-invasive biomarkers for cancer diagnosis. We profiled the EV proteome from 233 human patients using LC-MS/MS, including stage I‑IV tumors with matched non‑tumor colon tissues (n = 50 each; n = 100), paired pre‑/post‑operative plasma (n = 90) and healthy plasma (n = 43). Circulating EVs contained both tumor-specific and stromal/immune cell-derived proteins, reflecting the systemic nature of EV biology in the cancer setting. Proteomic analysis identified 745 proteins enriched in tumor-derived EVs (e.g., SRPK1, THBS2) and 127 proteins enriched in adjacent tissues. Plasma EVs revealed 166 proteins enriched in COAD (e.g., UBA1, FCN1) and 233 enriched in healthy controls. Pathway analysis linked tumor EV cargo to angiogenesis, mRNA splicing, TGF‑β signalling and RNA translation. Notably, a cross-cancer comparison (pancreatic = 10, lung = 14 cases) revealed that 76% of tumor EV proteins were COAD-specific, highlighting tissue of origin specificity. We further developed a 10-protein EV panel comprising seven tumor-associated and three healthy-enriched EV proteins, which effectively distinguished COAD patients from healthy controls in the two validation cohorts (n = 104 and n = 215), achieving > 90% sensitivity for differentiating COAD from healthy and non-COAD colorectal conditions. Six weeks after curative resection, tumor-associated EV proteins decreased by > 70%, whereas healthy-associated proteins rebounded to baseline, indicating surgical responsiveness. Collectively, EV protein signatures provide a sensitive and tissue-specific window into tumor-host communication, further supporting blood-based early detection of COAD.

DOI10.1002/jev2.70278
Custom 1

https://www.ncbi.nlm.nih.gov/pubmed/41979056?dopt=Abstract

Alternate JournalJ Extracell Vesicles
PubMed ID41979056
PubMed Central IDPMC13077566
Grant List2022R1A2C4001879 / / National Research Foundation of Korea (NRF) grants /
2022M3A9F3016364 / / National Research Foundation of Korea (NRF) grants /
RS-2026-25469803 / / National Research Foundation of Korea (NRF) grants /
HI22C0353 / / Korea Health Industry Development Institute / Republic of Korea
RS-2023-00304686 / / Korea Health Industry Development Institute / Republic of Korea
RS-2025-25459033 / / Korea Health Industry Development Institute / Republic of Korea
RS-2025-25459146 / / Korea Health Industry Development Institute / Republic of Korea
RS-2023-00261820 / / Korea Health Industry Development Institute / Republic of Korea
6-2023-0172 / / Yonsei University College of Medicine /

Weill Cornell Medicine Gale and Ira Drukier Institute for Children's Health 413 E. 69th Street New York, NY 10021